Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Stands Firm As Canada Follows Britain, Japan In Dura Mater Suspension

This article was originally published in The Gray Sheet

Executive Summary

Health Canada's suspension of the medical device licence for Tutogen's Tutoplast Dura represents a virtual ban on the importation and sale of all human dura mater products throughout the country

You may also be interested in...



FDA Completes Human Dura Mater Classification, Undeterred By CJD Threat

FDA will classify human dura mater as a Class II device (with special controls), despite lingering concerns raised by cases of dura mater-transmitted Creutzfeldt Jakob Disease (CJD) abroad

FDA Completes Human Dura Mater Classification, Undeterred By CJD Threat

FDA will classify human dura mater as a Class II device (with special controls), despite lingering concerns raised by cases of dura mater-transmitted Creutzfeldt Jakob Disease (CJD) abroad

FDA Reasserts Dura Mater Device Status During Interim Preceding GTPs

FDA is moving forward with rules establishing human dura mater as a Class II medical device before the agency issues guidelines transitioning the product into the purview of tissue regulation

Related Content

UsernamePublicRestriction

Register

MT016440

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel